Date published: 2025-10-25

1-800-457-3801

SCBT Portrait Logo
Seach Input

PED7A Inhibitors

Chemical inhibitors of Phosphodiesterase 7A (PDE7A) can interact with the enzyme in a manner that blocks its function of hydrolyzing cyclic nucleotides such as cyclic adenosine monophosphate (cAMP). Compounds like Rolipram, Piclamilast, and BRL 50481 can bind to the active site of PDE7A where cAMP normally binds. This competitive inhibition results in the prevention of cAMP from accessing the catalytic site, thus inhibiting the breakdown of this cyclic nucleotide. Rolipram, which has been extensively studied in other PDEs, can serve as a prototype for this mode of inhibition. Piclamilast, on the other hand, may also cause a conformational change in PDE7A that reduces its enzymatic activity, indicating an allosteric mode of inhibition. Similarly, BRL 50481 can also occupy the active site of PDE7A, thereby preventing cAMP hydrolysis and leading to an increase in intracellular cAMP levels.

Other chemicals, such as Dipyridamole, Cilostazol, and Pentoxifylline, are known to exhibit inhibitory actions across various PDE families and can be considered as broad-spectrum or non-selective PDE inhibitors. Dipyridamole can inhibit PDE7A by occupying its active site, thus hindering the enzyme's ability to regulate cAMP levels within the cell. Cilostazol, while primarily targeting PDE3, can exhibit cross-reactivity towards PDE7A due to the structural similarities in the binding sites of these enzymes. Pentoxifylline can also bind to the active site of PDE7A, thus reducing the enzyme's activity. Additionally, other inhibitors like Sildenafil and Anagrelide, although known for their selectivity towards other PDE isoforms, can also inhibit PDE7A by competitive binding to the active site. Vinpocetine and Istradefylline, although more selective towards other PDE isoforms, can also serve as PDE7A inhibitors by preventing cAMP from being hydrolyzed. Lastly, SCH 51866 and Zaprinast can interact with PDE7A in a similar fashion, binding to the enzyme's active site and leading to an accumulation of cAMP due to decreased hydrolysis.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Rolipram

61413-54-5sc-3563
sc-3563A
5 mg
50 mg
$75.00
$212.00
18
(1)

Rolipram binds to the active site of PDE7A, preventing cAMP from accessing the catalytic site, thus inhibiting the hydrolysis of cAMP.

Piclamilast

144035-83-6sc-478653
5 mg
$300.00
(0)

Piclamilast may interact with binding sites on PDE7A, leading to a conformational change that reduces the enzyme's activity towards cAMP.

Dipyridamole

58-32-2sc-200717
sc-200717A
1 g
5 g
$30.00
$100.00
1
(1)

Dipyridamole can inhibit PDE7A by binding to its active site, which would block cAMP hydrolysis and increase intracellular cAMP levels.

Cilostazol

73963-72-1sc-201182
sc-201182A
10 mg
50 mg
$107.00
$316.00
3
(1)

Although primarily a PDE3 inhibitor, Cilostazol might cross-react with PDE7A due to structural similarities, competitively inhibiting the enzyme's activity.

Pentoxifylline

6493-05-6sc-203184
1 g
$20.00
3
(1)

Pentoxifylline, a non-selective PDE inhibitor, could theoretically inhibit PDE7A by binding to its active site, thereby reducing cAMP hydrolysis.

Anagrelide

68475-42-3sc-491875
25 mg
$147.00
(0)

Anagrelide inhibits several PDE isozymes and may inhibit PDE7A through competitive binding to the catalytic site.

Vinpocetine

42971-09-5sc-201204
sc-201204A
sc-201204B
20 mg
100 mg
15 g
$55.00
$214.00
$2400.00
4
(1)

Vinpocetine is known to inhibit PDE1 but could also bind to and inhibit PDE7A, preventing the hydrolysis of cAMP.

Istradefylline

155270-99-8sc-488406
1 g
$311.00
1
(0)

Istradefylline, a selective PDE inhibitor, may inhibit PDE7A by blocking the enzyme's catalytic site and thus inhibiting cAMP breakdown.

Zaprinast (M&B 22948)

37762-06-4sc-201206
sc-201206A
25 mg
100 mg
$103.00
$245.00
8
(2)

Zaprinast may inhibit PDE7A by binding to the enzyme's active site and preventing cAMP hydrolysis.